These are the only FDA-approved treatments for reestablishing cerebral blood flow in ischemic stroke patients, but many challenges exist, including a narrow therapeutic time window for thrombolytics, potential risk of cerebral hemorrhage, ischemic-reperfusion injury, neurotoxic effects of tPA, and risks associated with endovascular thrombectomy, if that is performed [54]. Here, PLAT is linked to ischemic stroke.